Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins

Vaccine. 2004 Nov 25;23(2):215-21. doi: 10.1016/j.vaccine.2004.05.015.


Modified vaccinia Ankara (MVA) recombinants expressing single or multiple RSV surface proteins (F or G) are promising potential vaccines. We studied humoral and cellular responses induced by MVA-F and MVA-G in mice, comparing them to a formalin inactivated RSV preparation (FI-RSV) known to increase disease severity. MVA-F or MVA-G vaccination enhanced weight loss during RSV challenge, but did not show the lung eosinophilia seen after FI-RSV vaccination. FI-RSV induced a stronger total RSV IgG response than the MVA recombinants, but very little IgG2a. MVA recombinants induced cytokine responses biased towards IFNgamma and IL-12, while FI-RSV induced strong IL-4/5 responses in the lungs during RSV challenge. Thus, MVA vaccines induce a favourable immune profile in RSV disease but retain the potential to enhance disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Interferon-gamma / genetics
  • Interferon-gamma / immunology*
  • Interleukin-2 / genetics
  • Interleukin-2 / immunology*
  • Mice
  • Mice, Inbred BALB C
  • Respiratory Syncytial Virus Vaccines / administration & dosage
  • Respiratory Syncytial Virus Vaccines / adverse effects*
  • Respiratory Syncytial Virus Vaccines / immunology
  • Respiratory Syncytial Virus, Human / immunology
  • T-Lymphocytes / immunology*
  • Vaccines, Inactivated / administration & dosage
  • Vaccines, Inactivated / adverse effects
  • Vaccines, Inactivated / immunology
  • Vaccines, Synthetic / immunology
  • Vaccinia virus / immunology*
  • Viral Proteins


  • Interleukin-2
  • Respiratory Syncytial Virus Vaccines
  • Vaccines, Inactivated
  • Vaccines, Synthetic
  • Viral Proteins
  • Interferon-gamma